Fax: (416) 946-4442
Fractionated stereotactic radiotherapy for acoustic neuroma†
Single-institution experience at the princess margaret hospital
Article first published online: 22 FEB 2007
Copyright © 2007 American Cancer Society
Volume 109, Issue 6, pages 1203–1210, 15 March 2007
How to Cite
Koh, E.-S., Millar, B.-A., Ménard, C., Michaels, H., Heydarian, M., Ladak, S., McKinnon, S., Rutka, J. A., Guha, A., Pond, G. R. and Laperriere, N. J. (2007), Fractionated stereotactic radiotherapy for acoustic neuroma. Cancer, 109: 1203–1210. doi: 10.1002/cncr.22499
Presented at the 1st Canadian Radiosurgery Society Meeting, Banff, Alberta March 4–5, 2005 (oral); the 19th Annual Meeting of Canadian Association of Radiation Oncology, Victoria, British Columbia, Sept 7–10, 2005, and European Cancer Conference (ECCO 13), Paris, France, Oct 30–Nov 3, 2005 (posters).
- Issue published online: 7 MAR 2007
- Article first published online: 22 FEB 2007
- Manuscript Accepted: 28 NOV 2006
- Manuscript Revised: 17 NOV 2006
- Manuscript Received: 29 AUG 2006
- acoustic neuroma;
- fractionated stereotactic radiotherapy;
- local control;
- hearing preservation;
The clinical outcome and toxicity of fractionated stereotactic radiotherapy (FSRT) was assessed for acoustic neuroma in 60 patients treated in a single institution.
Between October 1996 and February 2005, 60 patients received FSRT for acoustic neuroma (AN). The mean total dose applied was 50 Gy in single daily 2-Gy fractions over 5 weeks. The median irradiated tumor volume was 4.9 cm3 (range, 0.3–49.0 cm3). The median follow-up period was 31.9 months.
FSRT was well tolerated in all patients. The 5-year actuarial local control rate was 96.2% (95% CI: 91.1%–100.0%). Five-year actuarial progression-free survival was 92.8% (95% CI: 84.8%–100.0%). The overall hearing preservation rate was 77.3%. Five of 6 patients with initial cranial nerve V (CNV) numbness remained stable post-FSRT. Two of 3 patients with baseline trigeminal neuralgia improved with the remaining patient stable. All 3 patients with nonsurgically related facial nerve weakness either improved or achieved stability in function. There were no cases of new cranial nerve toxicity post-FSRT.
FSRT for the treatment of AN is safe, effective, and well tolerated. FSRT should thus be considered as an effective alternative treatment modality when compared with microsurgical resection or single fraction stereotactic radiosurgery. Cancer 2007. © 2007 American Cancer Society.